Abstract
Phenolic group in therapeutic drugs can be used for a prodrug modification to overcome various undesirable drug properties that may become pharmacological, pharmaceutical or pharmacokinetic barriers for application. Several strategies have been used in order to overcome the limited bioavailability of phenolic drugs. Classical design represents a nonspecific chemical approach to mask undesirable drug properties, limited bioavailability or chemical instability. Targeted prodrug design represents a new strategy for directed and efficient drug delivery. Particularly, targeting the prodrug to specific enzyme or specific membrane transporter has potential as selective drug delivery system mainly in cancer therapy. The article brings examples of ester, sulphate, carbamate, carbonate, phosphate and ether prodrugs as well as the limitations of these prodrug strategies. Some specific enzyme targets are also presented.
Keywords: Phenolic functional group, prodrug strategies, biochemical pathways, drug delivery
Current Pharmaceutical Design
Title: Prodrug Design of Phenolic Drugs
Volume: 16 Issue: 18
Author(s): J.M. Ferriz and J. Vinsova
Affiliation:
Keywords: Phenolic functional group, prodrug strategies, biochemical pathways, drug delivery
Abstract: Phenolic group in therapeutic drugs can be used for a prodrug modification to overcome various undesirable drug properties that may become pharmacological, pharmaceutical or pharmacokinetic barriers for application. Several strategies have been used in order to overcome the limited bioavailability of phenolic drugs. Classical design represents a nonspecific chemical approach to mask undesirable drug properties, limited bioavailability or chemical instability. Targeted prodrug design represents a new strategy for directed and efficient drug delivery. Particularly, targeting the prodrug to specific enzyme or specific membrane transporter has potential as selective drug delivery system mainly in cancer therapy. The article brings examples of ester, sulphate, carbamate, carbonate, phosphate and ether prodrugs as well as the limitations of these prodrug strategies. Some specific enzyme targets are also presented.
Export Options
About this article
Cite this article as:
Ferriz J.M. and Vinsova J., Prodrug Design of Phenolic Drugs, Current Pharmaceutical Design 2010; 16 (18) . https://dx.doi.org/10.2174/138161210791293042
DOI https://dx.doi.org/10.2174/138161210791293042 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting of Low-Molecular Weight Drugs to Mammalian Mitochondria
Drug Design Reviews - Online (Discontinued) Ceramide-Based Therapeutics for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Experimental Models of Discovery: Prediction and Protection must Proceed “Hand-in-Hand”
Current Neurovascular Research Multiple Protective Functions of Sigma1 Receptor
Current Protein & Peptide Science Enzymatic Properties and Physiological Roles of Cytosolic 5’-Nucleotidase II.
Current Medicinal Chemistry Real Time Analysis of Neurotransmitters in the Brain Using a Micro-Electrode System
Current Neurovascular Research Genetic Modification of Natural Killer Cells for Leukemia Therapies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry NAD Biosynthesis in Humans - Enzymes, Metabolites and Therapeutic Aspects
Current Topics in Medicinal Chemistry Imatinib Reduces the Vasculogenic Potential of Plastic Tumor Cells
Current Angiogenesis (Discontinued) Chest Pain in Children
Current Pediatric Reviews Clinical Importance and Potential Use of Small Molecule Inhibitors of Focal Adhesion Kinase
Anti-Cancer Agents in Medicinal Chemistry 1,2,3-Triazine Scaffold as a Potent Biologically Active Moiety: A Mini Review
Mini-Reviews in Medicinal Chemistry The ARRONAX Project
Current Radiopharmaceuticals Ras-Induced Resistance to Lapatinib is Overcome by MEK Inhibition
Current Cancer Drug Targets Protein Interaction Domains: Structural Features and Drug Discovery Applications (Part 2)
Current Medicinal Chemistry The Doublecortin Gene Family and Disorders of Neuronal Structure
Central Nervous System Agents in Medicinal Chemistry Gene Expression Profile Classification: A Review
Current Bioinformatics Targeted Therapy of the Insulin-Like Growth Factor-1 Receptor in Cancer
Combinatorial Chemistry & High Throughput Screening Effect of Synthetic Cannabinoid HU210 on Memory Deficits and Neuropathology in Alzheimers Disease Mouse Model
Current Alzheimer Research Modulation of the Cannabinoid System: A New Perspective for the Treatment of the Alzheimer’s Disease
Current Neuropharmacology